消息方面，目前2024年医保谈判已进入谈判/竞价阶段。根据国投证券，本次医保谈判里共有约41个国产独家创新药(含引进)通过形式审查，有望新增药品谈判：包括2023年7月1日至2024年6月30日之间新获批上市的28个创新药，以及2023年7月1日以前获批上市的13个创新药。① The impact of health insurance negotiations on pharmaceutical stocks? ② What is the reason for the rise of Clover Bio and Yiming Anke?
Financial Services, Oct. 29 (Editor: Hu Jiarong) Most Hong Kong pharmaceutical stocks strengthened today. As of press release, Clover Bio-B (02197.HK), IMMUNEONCO-B (01541.HK), BASECARE-B (02170.HK), and Pharmaceutical Kangde (02359.HK) had increased by 14.75%, 7.83%, 7.48%, and 4.08%, respectively.
Note: Performance of pharmaceutical stocks
In terms of news, the 2024 health insurance negotiations have now entered the negotiation/bidding stage. According to SDIC Securities, a total of about 41 domestically produced exclusive innovative drugs (including introduction) have passed the formal review, and it is expected that additional drug negotiations will be added: including 28 innovative drugs newly approved for marketing between July 1, 2023 and June 30, 2024, and 13 innovative drugs approved for marketing before July 1, 2023.
BOC International also pointed out that the tenth batch of national drug procurement reports shows that the entry threshold for this round of national procurement is the highest in history, and injections account for the highest proportion in history. It is expected that competition will be extremely intense, but for most prescription pharmaceutical companies, there are few large varieties involved, and the impact may be limited. The recommendation is based on the final variety list.
Some pharmaceutical stocks had the highest gains
Judging from the chart above, Clover Biotech and Yiming Anke had the highest gains. First, Clover Biotech issued an announcement stating that after evaluating the unused adjuvant bivalent RSV preF-trimer subunit vaccine candidate SCB-1019 (development of Trimer-Tag-protein trimerization vaccine technology platform) head-to-head comparison with GSK's RSVAREXVY using the AS01E adjuvant, more positive immunogenicity and safety data were obtained in elderly subjects.
Second, Yiming Angke issued an announcement stating that on October 25, 2024, the company submitted filing documents to the China Securities Regulatory Commission on the proposed implementation of full circulation of H shares to convert a total of 14.114 million shares of the company's unlisted shares into the company's H shares. As of the date of the announcement, the company has not completed the filing procedure of the China Securities Regulatory Commission, and the details of the implementation plan for conversion and listing have not yet been implemented.
